Sites across the Asia-Pacific region have quickly changed how they manage trials, and most are able to deliver the clinical trial services their clients need. Biotech companies are currently initiating more clinical trials in Asia and Australia/New Zealand than in North America. During this briefing we will also discuss how:
Hannah Tarrant has 18 years of clinical research experience including 10 years as a Project Manager across EU, US and APAC, and has been a Project Director at Novotech Australia for the last 4 years. In this role she provides senior level oversight for phase I to IV studies across the APAC region and multiple therapeutic areas. She has also led multiple initiatives across the company, most recently driving Novotech’s Project Management response to the COVID-19 pandemic.
Daniela joined Novotech in 2009 and since starting her role as Director of Clinical Operations ANZ in 2018 is responsible for the strategic planning and management of the clinical operations team to ensure project deliverables. Previous to Novotech, Daniela worked with Pfizer Pharmaceuticals. Daniela comes from a strong academic research background in cardiovascular and heart disease-related drug development and holds a BSc (Hons) and PhD in Chemistry.
Dr. Kim is responsible for overseeing Novotech’s operations and project delivery within the Asia region. Prior to joining Novotech, Dr. Kim worked at PRA Health Sciences as Director of Operations for North Asia. Dr. Kim is very experienced in Asia’s drug development industry, having managed operations for South Korea, Taiwan, China, Hong Kong, Singapore, Malaysia, Indonesia, Thailand, the Philippines and Japan. She has also worked at various positions in clinical development, medical affairs, and pharmacovigilance at GSK.
Alejandro is part of the Oncology Senior Leadership Team and is responsible for both small molecule and biologic programs. Prior to this role, Alex was Executive Medical Director at Oncology Early Development Strategy & Innovation at Novartis Pharmaceuticals Corporation. Alex was also Senior Director Late Development at Merck & Co., Inc. He played a key role in Pembrolizumab (KEYTRUDA®) Breakthrough Therapy Designation and in the Supplemental Biologics License Application (sBLA) for Hodgkin lymphoma.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.